{"entity":{"id":"nct05908734","kind":"trial","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Cetrelimab and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05908734 by Janssen Research & Development, LLC, with 71 participants enrolled, started 2023-05-18 and due to reach its primary completion in 2027-01-31. Interventions recorded: Cetrelimab and Amivantamab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05908734","url":"https://clinicaltrials.gov/study/NCT05908734"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cetrelimab","amivantamab"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05908734","phase":"1/2","setting":"A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":71,"outcomes":[]},"route":"/trials/nct05908734/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}